VANDA PHARMACEUTICALS INC. Restricted Cash and Cash Equivalents
VANDA PHARMACEUTICALS INC. (VNDA) had Restricted Cash and Cash Equivalents of $469.00 thousand as of 2025-06-30, per its 10-Q filed 2025-07-31.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-07-31
- 2025-06-30: Restricted Cash and Cash Equivalents $469.00K.
- 2025-03-31: Restricted Cash and Cash Equivalents $469.00K.
- 2024-12-31: Restricted Cash and Cash Equivalents $469.00K.
- 2024-09-30: Restricted Cash and Cash Equivalents $469.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-06-30 | $469.00K 10-Q · filed 2025-07-31 |
| 2025-03-31 | $469.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $469.00K 10-K · filed 2025-02-14 |
| 2024-09-30 | $469.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $469.00K 10-Q · filed 2025-07-31 |
| 2024-03-31 | $469.00K 10-Q · filed 2025-05-08 |
| 2023-12-31 | $469.00K 10-K · filed 2025-02-14 |
| 2023-09-30 | $469.00K 10-Q · filed 2024-11-07 |
| 2023-06-30 | $469.00K 10-Q · filed 2024-08-01 |
| 2023-03-31 | $469.00K 10-Q · filed 2024-05-09 |
| 2022-12-31 | $469.00K 10-K · filed 2024-02-08 |
| 2022-09-30 | $469.00K 10-Q · filed 2023-11-09 |
| 2022-06-30 | $516.00K 10-Q · filed 2023-07-28 |
| 2022-03-31 | $518.00K 10-Q · filed 2023-05-03 |
| 2021-12-31 | $519.00K 10-K · filed 2023-02-09 |
| 2021-09-30 | $519.00K 10-Q · filed 2022-11-03 |
| 2017-12-31 | $700.00K 10-K · filed 2018-02-15 |
| 2016-12-31 | $800.00K 10-K · filed 2018-02-15 |
| 2015-12-31 | $800.00K 10-K · filed 2017-02-17 |
| 2014-12-31 | $800.00K 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |